Calidi Biotherapeutics, Inc. Income Statement
CLDI|1 years of annual SEC 10-K data (FY2023-FY2023)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.02 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 |
|---|---|
| SG&A Expense | $16.0M |
| R&D Expense | $13.0M |
| Operating Income | -$29.0M |
| Interest Expense | $1.1M |
| Income Tax | $16.0K |
| Net Income | -$29.2M |
| EPS (Basic) | $2.99 |
| EPS (Diluted) | $2.99 |
| Shares Outstanding | 8.6M |